Silo Pharma Raises $4 Million in Private Placement as Shares Fall 28%
The at‑the‑market deal issues 619,965 shares plus two warrant series exercisable at $6.21, creating potential dilution with up to $7.7 million in additional proceeds.
Overview
- Silo Pharma said it entered definitive agreements to sell 619,965 common shares or pre‑funded warrants plus Series A‑3 and short‑term A‑4 warrants priced at $6.452 per unit.
- The company expects roughly $4.0 million in upfront gross proceeds and up to about $7.7 million more if all warrants are exercised for cash at a $6.21 strike price.
- The warrants are exercisable immediately with Series A‑3 lasting five years after resale registration and Series A‑4 expiring 18 months after that registration becomes effective.
- Market reaction was swift: shares plunged about 28% in morning trading on July 10, reflecting investor concern that the new securities will expand the share count and pressure per‑share value.
- Silo used exemptions under Section 4(a)(2)/Regulation D and agreed to file resale registration statements with the SEC; the company said net proceeds will fund working capital and general corporate needs.